FDA Update: May/June 2012
Drug Safety Communication on lenalidomide (Revlimid); FDA approval for pazopanib (Votrient)
Diagnosis & Disease Information
Bisphosphonates reduce fractures, pain of multiple myeloma
Adding bisphosphonates to myeloma treatment decreases fractures of the vertebra and bone pain, affirm the results of a review of 20 trials.
Posttransplant lenalidomide can slow down multiple myeloma
Lenalidomide use after autologous stem-cell transplant significantly improved progression-free and overall survival in patients with myeloma.
Lenalidomide maintenance beneficial in multiple myeloma
Three studies show benefit of lenalidomide, including after induction therapy or stem-cell transplant.
Experimental agent acts against aggressive lymphoma subtype
The drug ibrutinib can provide significant anticancer responses with modest side effects in persons with diffuse large B-cell lymphomas (DLBCLs).
Diagnosis delayed for certain cancers and certain patients
A large UK study found a wide variation between cancer types in patients who had visited their general practitioner 3 or more times before cancer diagnosis.
Multiple Myeloma: Finding Resources and Support
This fact sheet reviews a number of resources available to patients coping with multiple myeloma, from the health care team to in the community.
Multiple Myeloma: Making the Most of Your Medical Appointments
Many people see their cancer care as a collaboration. This fact sheet provides tips for patients with multiple myeloma for improving communication with providers during office visits.
Cell protein raises blood levels of multiple myeloma drug
The anti-inflammatory agent lenalidomide interacts with a molecule that pumps potentially toxic chemicals out of cells, raising blood levels of the drug and increasing side effects.
Women and blacks experience greater cancer-related pain
Racial and sex disparities exist in cancer-related pain rates, according to a survey of diverse cancer survivors by Carmen R. Green, MD, of the University of Michigan, and colleagues.
- Loading...
Loading...
Loading... 
Loading...